𩺠Peripheral Arterial Disease (PAD) Management
In Elderly Patients with Diabetes & Hypertension
šÆ Treatment Goals
š¹ 1. Lifestyle Modifications (Foundation of Treatment)
Smoking cessation
(if applicable)
Exercise therapy
Supervised walking program ā„30 min/day, 3Ć/week
Diet
Heart-healthy, low-sodium, diabetic-friendly diet
Weight loss
if overweight (BMI > 25)
š¹ 2. Antiplatelet Therapy
To reduce the risk of MI, stroke, or vascular death.
Aspirin 75ā100 mg daily
Clopidogrel 75 mg daily
(preferred if aspirin-intolerant)
š” Note: Do not combine routinely unless there's another indication (e.g., recent stent).
š¹ 3. Statin Therapy
All patients with PAD should be on a high-intensity statin unless contraindicated.
Atorvastatin 40ā80 mg daily
Rosuvastatin 20ā40 mg daily
šÆ Goal: LDL < 1.8 mmol/L (or at least 50% reduction)
š¹ 4. Blood Pressure Control
Target: < 130/80 mmHg (especially in diabetics)
Preferred agents:
ACE inhibitors or ARBs
(e.g., Ramipril, Perindopril, or Losartan) ā vascular protection
Add dihydropyridine CCB
(e.g., Amlodipine) if needed for further BP control
ā ļø Avoid: beta-blockers if possible in symptomatic PAD (may worsen claudication)
š¹ 5. Diabetes Management
Target HbA1c: ⤠7% (individualized based on comorbidity and frailty)
Preferred agents:
SGLT2 inhibitors
(e.g., empagliflozin) ā cardiovascular benefit
GLP-1 receptor agonists
(e.g., liraglutide) ā reduces CV risk
ā ļø Avoid: agents that increase hypoglycemia risk in elderly (e.g., sulfonylureas)
š¹ 6. Symptom Management ā Claudication
Cilostazol 100 mg twice daily
(unless heart failure is present)
Consider alternatives:
naftidrofuryl or pentoxifylline (less effective)
š¹ 7. Revascularization (If indicated)
Consider in cases of:
Options:
Endovascular
(angioplasty ± stent)
Surgical bypass
š§ Summary Table
Category | Recommended |
---|---|
Lifestyle | Smoking cessation, exercise, diet |
Antiplatelet | Aspirin or Clopidogrel |
Lipid control | High-intensity statin |
Hypertension | ACEi/ARB ± CCB (avoid beta-blockers if possible) |
Diabetes | SGLT2i / GLP-1 RA, avoid sulfonylureas |
Claudication | Cilostazol (unless HF) |
Revascularization | For severe/critical cases |